201 related articles for article (PubMed ID: 21674561)
21. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.
Shata MT; Tricoche N; Perkus M; Tom D; Brotman B; McCormack P; Pfahler W; Lee DH; Tobler LH; Busch M; Prince AM
Virology; 2003 Sep; 314(2):601-16. PubMed ID: 14554088
[TBL] [Abstract][Full Text] [Related]
22. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
Merat SJ; Bru C; van de Berg D; Molenkamp R; Tarr AW; Koekkoek S; Kootstra NA; Prins M; Ball JK; Bakker AQ; de Jong MD; Spits H; Beaumont T; Schinkel J
J Hepatol; 2019 Jul; 71(1):14-24. PubMed ID: 30797052
[TBL] [Abstract][Full Text] [Related]
23. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
[TBL] [Abstract][Full Text] [Related]
24. Immunity in hepatitis C virus infection.
Prince AM
Vox Sang; 1994; 67 Suppl 3():227-8. PubMed ID: 7526553
[TBL] [Abstract][Full Text] [Related]
25. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development.
Bukh J; Forns X; Emerson SU; Purcell RH
Intervirology; 2001; 44(2-3):132-42. PubMed ID: 11509874
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C vaccines: Inducing and challenging memory T cells.
Shiina M; Rehermann B
Hepatology; 2006 Jun; 43(6):1395-8. PubMed ID: 16729320
[TBL] [Abstract][Full Text] [Related]
27. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.
Rollier C; Depla E; Drexhage JA; Verschoor EJ; Verstrepen BE; Fatmi A; Brinster C; Fournillier A; Whelan JA; Whelan M; Jacobs D; Maertens G; Inchauspé G; Heeney JL
J Virol; 2004 Jan; 78(1):187-96. PubMed ID: 14671100
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C cross-genotype immunity and implications for vaccine development.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Wong J; Tyndall MW; Janjua NZ;
Sci Rep; 2017 Sep; 7(1):12326. PubMed ID: 28951612
[TBL] [Abstract][Full Text] [Related]
29. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma.
Yu MY; Bartosch B; Zhang P; Guo ZP; Renzi PM; Shen LM; Granier C; Feinstone SM; Cosset FL; Purcell RH
Proc Natl Acad Sci U S A; 2004 May; 101(20):7705-10. PubMed ID: 15136748
[TBL] [Abstract][Full Text] [Related]
30. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.
Park SH; Shin EC; Capone S; Caggiari L; De Re V; Nicosia A; Folgori A; Rehermann B
Gastroenterology; 2012 Oct; 143(4):1048-60.e4. PubMed ID: 22705008
[TBL] [Abstract][Full Text] [Related]
31. Immune control and failure in HCV infection--tipping the balance.
Dustin LB; Cashman SB; Laidlaw SM
J Leukoc Biol; 2014 Oct; 96(4):535-48. PubMed ID: 25015956
[TBL] [Abstract][Full Text] [Related]
32. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.
Morin TJ; Broering TJ; Leav BA; Blair BM; Rowley KJ; Boucher EN; Wang Y; Cheslock PS; Knauber M; Olsen DB; Ludmerer SW; Szabo G; Finberg RW; Purcell RH; Lanford RE; Ambrosino DM; Molrine DC; Babcock GJ
PLoS Pathog; 2012; 8(8):e1002895. PubMed ID: 22952447
[TBL] [Abstract][Full Text] [Related]
33. Immunity elicited by hepatitis C virus.
Farci P; Orgiana G; Purcell RH
Clin Exp Rheumatol; 1995; 13 Suppl 13():S9-12. PubMed ID: 8730469
[TBL] [Abstract][Full Text] [Related]
34. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.
Bassett SE; Thomas DL; Brasky KM; Lanford RE
J Virol; 1999 Feb; 73(2):1118-26. PubMed ID: 9882313
[TBL] [Abstract][Full Text] [Related]
35. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.
Farci P; Shimoda A; Wong D; Cabezon T; De Gioannis D; Strazzera A; Shimizu Y; Shapiro M; Alter HJ; Purcell RH
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15394-9. PubMed ID: 8986822
[TBL] [Abstract][Full Text] [Related]
36. Organ system view of the hepatic innate immunity in HCV infection.
Bang BR; Elmasry S; Saito T
J Med Virol; 2016 Dec; 88(12):2025-2037. PubMed ID: 27153233
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees.
Shata MT; Anthony DD; Carlson NL; Andrus L; Brotman B; Tricoche N; McCormack P; Prince A
J Viral Hepat; 2002 Nov; 9(6):400-10. PubMed ID: 12431201
[TBL] [Abstract][Full Text] [Related]
38. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response.
Meyer MF; Lehmann M; Cornberg M; Wiegand J; Manns MP; Klade C; Wedemeyer H
Virol J; 2007 Jun; 4():58. PubMed ID: 17562015
[TBL] [Abstract][Full Text] [Related]
39. In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus.
Esumi M; Zhou YH; Tanoue T; Tomoguri T; Hayasaka I
Vaccine; 2002 Aug; 20(25-26):3095-103. PubMed ID: 12163260
[TBL] [Abstract][Full Text] [Related]
40. Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length.
Kell A; Stoddard M; Li H; Marcotrigiano J; Shaw GM; Gale M
J Virol; 2015 Nov; 89(21):11056-68. PubMed ID: 26311867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
